Clinical Trial Update: Phase 1b/2 Study of Combination 177Lu Girentuximab Plus Cabozantinib and Nivolumab in Treatment naïve Patients With Advanced Clear Cell RCC [Phase 1, Phase 2]

View source ↗

Summary

Phase 1b/2 trial evaluating a triple combination of 177Lu-girentuximab, cabozantinib, and nivolumab in treatment-naïve patients with advanced clear cell renal c…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Clear Cell Renal Cell Carcinoma

Drugs mentioned

• 177Lu-girentuximab (girentuximab labeled with Lutetium-177)
• cabozantinib (cabozantinib)
• nivolumab (nivolumab)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Advanced Cancer, Clear Cell Renal Cell Carcinoma | Phase 1, Phase 2 | Status: RECRUITING